What Discovery Life Sciences does

Discovery Life Sciences is a privately held biospecimen solutions and specialty laboratory services company headquartered in Huntsville, Alabama, serving biopharmaceutical companies, cell and gene therapy developers, clinical diagnostics firms, and academic/government research institutions. The company operates a vertically integrated platform that combines assay-ready biospecimens (dissociated tumor and tissue cells, PBMCs, BMMCs, FFPE tissues, primary hepatocytes, patient-derived tumoroids, and AllCells cell and gene therapy starting materials) with multi-omic characterization services spanning genomics, proteomics, molecular pathology, and cell biology.

Its core technology stack centers on proprietary products such as SpecimenSeq NGS-characterized biospecimens with documented genomic profiles, the Luminos 164-gene IVDR-compliant comprehensive genomic profiling panel deployed in-house at the Kassel, Germany facility under Health Institution status, and the Gentest line of cryopreserved hepatocytes and ADME services supporting over 1,200 IND-enabling studies. The company supplements these with AI-powered digital pathology through PathAI AISight and Mindpeak partnerships for tumor quantification and biomarker interpretation.

The business model combines one-time biospecimen product sales (transacted through the Discovery BioStore e-commerce platform and direct sales) with professional services revenue from specialty lab work, custom prospective biospecimen collections, and IVDR-compliant clinical trial testing. Pricing follows a unit-based model with volume discounts (e.g., 10-40% off with quantity tiers and additional bundle discounts), and the go-to-market is hybrid — enterprise field sales for large biopharma and CGT contracts, inside sales for mid-market, and e-commerce for SMB and individual researchers — supported by a Discovery Partners network of nearly 200 clinical sites and 10,000+ recallable donors across the US and Europe.

Name

Discovery Life Sciences

Legal name

Discovery Life Sciences

Website

https://dls.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Discovery Life Sciences is a privately held biospecimen and specialty lab services company serving biopharma, cell and gene therapy developers, and diagnostics firms with assay-ready biospecimens, multi-omic characterization, and IVDR-compliant genomic profiling.

Ownership category

akta.pro rank

Product category

Biospecimen and Specialty Laboratory Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA)

akta.pro secondary industries

DMPK / ADME & Bioanalysis (HLAGAFAC), Cell-Based & Potency Assays (Bioassays) (HLAGADAH), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Biospecimen procurement
• Multi-omic lab services
• Comprehensive genomic profiling
• Cell therapy starting materials
• Molecular pathology services

Headquarters

HQ city

Huntsville

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Others

Revenue model

1. Biospecimen Product Sales: Sale of assay-ready biospecimens including FFPE tissues, DTCs, tumoroids, PBMCs, BMMCs, blood products, hepatocytes, and matched sets. Products sold directly via Discovery BioStore e-commerce and through sales team for larger/custom orders.
2. Specialty Lab Services: Multi-omic biomarker services spanning genomics (WGS, WES, RNA-Seq, targeted panels), proteomics (Olink, mass spec), molecular pathology (IHC, multiplex IF, ISH), flow cytometry, and cell biology services. Services provided at CLIA/CAP certified labs.
3. Custom/Prospective Collections: Custom donor recruitment and prospective biospecimen collection services with specific inclusion criteria, timelines, and analytical requirements tailored to client studies.
4. IVDR-Compliant Genomic Testing: Luminos® Comprehensive 164-gene CGP panel delivered as IVDR-compliant laboratory-developed test with prospective clinical trial use capability in EU.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Discovery Life Sciences provides assay-ready human biospecimens (FFPE tissues, dissociated tumor cells, PBMCs, BMMCs, tumoroid cell lines, cryopreserved primary hepatocytes, and AllCells® cell and gene therapy starting materials) combined with multi-omic specialty laboratory services (NGS genomics, Olink and mass-spectrometry proteomics, IHC and multiplex IF molecular pathology, flow cytometry/cell biology, and Gentest® ADME drug metabolism testing). The company serves biopharmaceutical, cell & gene therapy, and clinical diagnostics customers with research-use and IVDR-compliant clinical trial testing products, distributing through Discovery BioStore™ e-commerce and dedicated enterprise sales.

Product overview

Discovery Life Sciences operates as a biospecimen solutions and specialty lab services company offering an integrated portfolio combining assay-ready biospecimens with multi-omic laboratory services. The core product portfolio spans biospecimen types including Dissociated Tumor Cells (DTCs), PBMCs, BMMCs, FFPE tissues, hepatocytes (via Gentest® brand), and tumoroid cell lines (including AllCells® CGT Starting Materials). Specialty lab services include Genomics Services (WGS, RNA-Seq, TSO500, single cell), Proteomics Services (Olink, mass spec), Molecular Pathology Services (IHC, multiplex IF, digital pathology), Cell Biology Services (flow cytometry, spatial biology), and Gentest® ADME Services. The Luminos® platform provides IVDR-compliant comprehensive genomic profiling (164-gene CGP panel) for EU oncology trials. SpecimenSeq™ products offer pre-sequenced, NGS-characterized biospecimens enabling rapid cohort building without de novo sequencing. AI-powered digital pathology capabilities are integrated through partnerships with Mindpeak and PathAI (AISight) for enhanced biomarker quantification and reduced interpretation variability.

Differentiator

Problem solved

Functional benefit

Brands

• AllCells®: Cell and gene therapy starting materials including RUO and GMP products, fresh and cryopreserved leukopaks, and isolated cellular products
• Luminos®
• Gentest®
• SpecimenSeq™
• OncoPro™
• Discovery BioStore™
• Discovery Partners®

Products and services

• Luminos® Comprehensive A 164-gene pan-tumor comprehensive genomic profiling panel deployed in-house at the Kassel, Germany facility under IVDR-compliant Health Institution status, delivering results in 7-10 business days for oncology clinical trial enrollment screening and companion diagnostic development.
• Luminos® Clinical Genomics Comprehensive genomic profiling platform encompassing tissue-based and liquid biopsy panels for oncology clinical trials, supporting enrollment screening and companion diagnostic development in EU markets.
• SpecimenSeq™ NGS-Characterized Biospecimens Pre-sequenced human biospecimens including FFPE tissues, DTCs, matched FFPE/plasma sets, and BMMC/PBMC sets, characterized with 500+ genes across oncology indications, enabling rapid biomarker validation and cohort building without de novo sequencing costs.
• Tumoroid Cell Lines, OncoPro™ Medium-Derived Patient-derived 3D tumoroid cell lines expanded in Gibco OncoPro Tumoroid Culture Medium, characterized by whole exome sequencing and RNA sequencing, serving as predictive tools for drug efficacy and mechanism of action studies with matched biospecimens available.
• AllCells® CGT Starting Materials Cell and gene therapy starting materials including RUO and GMP cryopreserved leukopaks, mobilized and non-mobilized HSPCs, and isolated TBNK cells, monocytes, and PBMCs from a network of 10,000+ well-characterized recallable donors with 98% deliverability.
• Dissociated Tumor & Tissue Cells (DTCs) Cryopreserved single-cell suspensions derived from solid tumors or normal tissues via proprietary mechanical and enzymatic dissociation, validated as alternatives to fresh tissue with guaranteed cell counts, characterized by flow cytometry and HLA-A02 typing.
• Peripheral Blood Mononuclear Cells (PBMCs) Healthy and diseased PBMCs from 1,100+ patients isolated via density gradient methods, cryopreserved with immunophenotyping by flow cytometry, available as matched sets with BMMCs, DTCs, FFPE, and tumoroids for immunology, oncology, and cell therapy research.
• Bone Marrow Mononuclear Cells (BMMCs) Immunophenotypically characterized diseased and normal BMMCs isolated from bone marrow aspirates via density gradient centrifugation, with multiparametric flow cytometry tailored to disease indication and HLA-A02 typing.
• Gentest® Cryopreserved Primary Hepatocytes Primary hepatocytes assessed for plateability, viability, confluency, P450 inducibility, transporter activity, and post-thaw performance, available in plateable, inducible, suspension, pooled, MetMax permeabilized, and On-Demand pre-plated formats for ADME/DMPK, drug-drug interaction, and hepatotoxicity studies.
• FFPE Tissue Samples Hyper-annotated FFPE tissue blocks with 12-point QC, triple-pathologist review, AI tumor quantification, and 40x digital H&E images, available from 60,000+ blocks across 18,000+ patients with matched plasma, DTCs, and flash frozen tissue options.
• Genomics Services Comprehensive genomic services including whole genome sequencing, RNA-sequencing, exome and targeted sequencing (TSO500), single cell sequencing, epigenomic sequencing, and NGS bioinformatics across advanced sequencing platforms.
• Proteomics Services Proteomic services including Olink-certified Target panels (Reveal, Target 96 Inflammation, Target 48 Cytokine/Immune Surveillance), mass spectrometry, plasma proteomics, and global proteomics for biomarker profiling.
• Molecular Pathology Services Pathologist-driven molecular pathology services including immunohistochemistry (IHC), multiplex immunofluorescence, Bio-Techne Spatial COMET HyperPlex IF, histology and digital pathology, in situ hybridization, and quantitative gene expression analysis.
• Cell Biology Services Cell-based services including flow cytometry and cell sorting (clinical and research), live-cell imaging, cytokine analysis, single-cell genomics, spatial biology, and hematopoietic CFC assays (myeloid/erythroid, megakaryocytic, blood cancer hematotoxicity).
• Gentest® ADME Services In vitro ADME services including enzyme induction, enzyme inhibition, reaction phenotyping, and transporter interaction studies, having supported over 1,200 IND-enabling studies for drug metabolism and toxicology assessment.
• SpecimenSeq™ FFPE Tissues Pre-sequenced FFPE tissues with approximately 60,000+ variants from 500+ genes across 19 oncology indications and 1,200+ unique patients, ethically collected from treatment-naive cancer patients with clinical and pathology reports.
• SpecimenSeq™ FFPE & Plasma Matched Sets NGS-characterized matched sets of FFPE tissues and double-spun plasma from the same donor, with 1,200+ variants from 54 clinically relevant genes across 30 oncology indications, supporting liquid biopsy research and ctDNA analysis.
• SpecimenSeq™ DTCs and Matched Sets Pre-sequenced dissociated tumor cells with 800+ variants from 50+ clinically relevant genes across 13 oncology indications, characterized with DNA (64 genes) and RNA fusion content (6 primary genes including ALK, NTRK1, ROS1, RET variants), available with matched PBMCs and FFPE.
• SpecimenSeq™ BMMCs & PBMCs NGS-characterized bone marrow mononuclear cells and peripheral blood mononuclear cells from AML and MDS patients, sequenced using Illumina TruSight Myeloid Panel covering 54 genes with 94% success rate, with QCI interpretive reports.

Quantifiable outcome

• Reduce screening costs with pre-sequenced biospecimens
• +2 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability4 records

Feature7 records

Partnerships

Six partnerships are on record, tiered strategic and core.

• MindpeakstrategicTechnology or Integration · 24 March 2026Strategic partnership to integrate AI-powered digital pathology for biomarker analysis in global clinical trials. Combines Mindpeak's AI platform with Discovery's tissue biomarker services and pathologist training programs to reduce variability in immunohistochemistry and multiplex immunofluorescence interpretation. Formal introduction planned for AACR Annual Meeting 2026 in San Diego.
• PathAIcoreTechnology or Integration · 31 January 2025Partnership to deploy AI-powered pathology solutions globally, marking the first large-scale deployment of AI in a commercial biobank. Focuses on enhancing drug development and diagnostics through digital biospecimen analysis, enabling automation and quantitative insights in pathology workflows. Collaboration aims to develop custom AI tissue analysis panels.
• Thermo Fisher ScientificcoreTechnology or IntegrationStrategic partnership for tumoroid cell line portfolio. Discovery offers tumoroid cell lines licensed from Thermo Fisher Scientific derived in Gibco™ OncoPro™ Tumoroid Culture Medium. These sourced lines complement Discovery's own tumoroid products, meeting wider range of cancer indications.
• QiagencoreTechnology or IntegrationNGS results delivered via Qiagen Clinical Insights (QCI) report including pathogenicity assessment, clinical significance according to guidelines, predicted protein changes, drug treatment relevance, and active clinical trial matching.
• IlluminacoreTechnology or IntegrationUtilizes Illumina TruSight Oncology 500 for comprehensive genomic profiling and TruSight Myeloid Panel for hematological oncology characterization, enabling detection of DNA and RNA variants across solid tumor and hematology indications.
• OlinkcoreTechnology or IntegrationOlink-certified service provider offering Target 96 Inflammation, Target 48 Cytokine, Immune Surveillance Panels, and customizable Flex and Focus options for proteomics services.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Bio-Techne: Large public life science tools company spanning reagents, proteomics (ProteinSimple, Olink), ExoDx, and biospecimen-adjacent products. Overlaps with Discovery across proteomics services, specialty lab tools, and cell/gene therapy reagents, though Bio-Techne's portfolio is far broader and more reagent-focused than Discovery's biospecimen-centric model.
• Charles River Laboratories: Large public CRO with extensive preclinical services including research models, biospecimens, and ADME/toxicology offerings that overlap with Discovery's Gentest® franchise and broader biospecimen business. Competes for IND-enabling study contracts and biopharma procurement RFPs.
• Labcorp Drug Development: Major clinical trial and specialty laboratory services provider through its Labcorp Drug Development and Central Labs businesses. Competes in CLIA/CAP clinical trial testing, genomic profiling, and biospecimen logistics for global pharma trials.
• IQVIA: Global clinical research services and lab services provider with significant biospecimen and genomic testing capabilities for clinical trials. Overlaps with Discovery on prospective collections, central lab services, and global trial support across the same biopharma customer base.

Direct peers

• BioIVT: Direct competitor focused on biospecimen procurement and specialty lab services for biopharma and diagnostics. Both companies compete head-to-head in FFPE, fresh/frozen tissues, biofluids, and cell products for research and clinical trial use, with similar customer bases in pharma R&D.
• CellGenix: Cell and gene therapy starting materials and reagents supplier, now part of Sartorius. Directly comparable to Discovery's AllCells® CGT starting materials franchise in leukopaks, PBMCs, and GMP cellular inputs for cell therapy manufacturing.
• SeraCare (LGC Clinical Diagnostics): Provider of clinical genomics reference materials, biospecimens, and IVDR-aligned diagnostic reagents now part of LGC. Directly comparable to Discovery's Luminos® CGP and SpecimenSeq™ offerings in clinical trial genomics and biomarker assay development.

Emerging players

• Cureline: Clinical biospecimen CRO focused on human tissue procurement for translational research and diagnostics development. Smaller than Discovery but competes for oncology biospecimen RFPs in EU and US with prospective collection capabilities.
• AMSBIO: Specialty biospecimen and life science reagent supplier with focus on primary cells, stem cells, and 3D culture models including tumoroids. Competes with Discovery's viable cell products, tumoroid, and primary cell offerings in the academic and biotech research market.
• REPROCELL: Specialty biospecimen and iPSC/cell products supplier with focus on regenerative medicine and drug discovery. Comparable in the primary cell and tumoroid-adjacent categories, though smaller and more regenerative-medicine focused than Discovery's broad oncology-heavy mix.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks4 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/discoverylifesciences

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A7 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Discovery Life Sciences